Skip To Main Content
Armida D'Incecco on Muck Rack

Armida D'Incecco

As seen in: Frontiers
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Armida

Contact Armida, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

|
By Murali M. Yallapu, Ana Isabel Fraguas, Zongming Li, Armida D'Incecco
| Frontiers
1 Introduction Lung cancer is the second most common cancer worldwide and the leading cause of cancer deaths, accounting for 11.4% of new cancers and 18% of cancer-related deaths in 2020 (1). According to statistics, NSCLC accounts for 80%–90% of all lung cancer diagnoses (2). Surgical resection is the main treatment modality for early-stage NSCLC; however, the prognosis and 5-year survival rate of patients after surgery remain unsatisfactory.
Open in Who Shared Issue with article?
See all 1 articles